AD04 Demo Batch Clears Dissolution Hurdle, Unlocking Phase 3 Production

Adial Pharmaceuticals has cleared a critical manufacturing threshold for its lead investigational compound AD04, completing a demonstration batch that met all prespecified test specifications for dissolution, content uniformity, and blend uniformity. For QA and manufacturing teams navigating CDMO transitions ahead of Phase 3 registration campaigns, the result signals that the technical process transfer to a new contract development and manufacturing organization held -- a milestone that is frequently where small-cap sponsors encounter costly delays under FDA IND requirements.

The demonstration batch was a prerequisite step before clinical and registration batch production could begin for the planned Phase 3 program targeting Alcohol Use Disorder (AUD). Critically, the transferred process matched the dissolution profile of the previous Phase 2 batch, satisfying the comparability requirement that regulators and sponsors use to confirm manufacturing continuity across sites and scales. Dissolution profile matching in a CDMO-to-CDMO transfer is among the more technically demanding elements of process validation, particularly for oral solid dosage forms where release kinetics directly affect clinical performance.

According to Adial, the successful tech transfer also achieved efficiencies in both manufacturing and analytical capability at the new CDMO. The company states the completed demonstration batch enables production of the clinical and registration batches required to conduct the trial, as well as the data needed to support IND updates with the FDA. AD04 is described as a genetically targeted serotonin-3 receptor antagonist being developed for heavy-drinking patients carrying certain target genotypes, identified through a proprietary diagnostic genetic test. The ONWARD Phase 2 study previously showed reductions in drinking with no overt safety or tolerability concerns, according to the company.

Regulatory pathway context: Under 21 CFR Part 211 and ICH Q10 quality system principles, demonstration or engineering batches serve as the documented evidence base for process understanding before a formal validation campaign. For a registration batch intended to support an NDA or BLA submission, the dissolution data generated here will likely form part of the comparability package submitted to FDA. Plant heads and regulatory affairs leads overseeing similar CDMO transitions should note that blend uniformity and content uniformity sign-off at this stage reduces the risk of manufacturing-related clinical holds downstream.

Adial President and CEO Cary Claiborne stated the completion "positions Adial to effectively progress our plans for the planned clinical trial program" and will assist with ongoing FDA discussions. The company, headquartered in Glen Allen, Virginia, is listed on NASDAQ under the ticker ADIL. Additional program information is available at www.adial.com. This article is based solely on a company press release dated April 22, 2026.